HELX ETF (Franklin Genomic Advancements ETF) is managed by Franklin Templeton Investments (US) with $29.1M in net assets. HELX expense ratio is 0.50%, holding 65 positions across sectors including Unknown, Information Technology. Inception date: 2020-02-25.

HELX performance shows a YTD return of 9.31%. The 1-year return is 44.86% and the 5-year return is -4.94%.

HELX top holdings include Astrazeneca Plc Adr (2.7%), Anaptysbio Inc (1.0%), Agilent Technologies Inc (0.6%), Bio-Rad Laboratories-A Common Stock (0.3%). View all HELX holdings, sector breakdown, or dividend history.

HELX can be compared against other funds using the overlap calculator or side-by-side comparison tool. HELX alternatives are available via the screener, along with tax-loss harvesting opportunities.